

**Enterprise P&T Meeting
Committee Meeting Minutes
July 25, 2022**

Voting Members Present

Antypas, Christopher, PharmD	Elebra, Rogers, PharmD	Martin, Kelly, PharmD	Robinson, Michelle, PharmD
Batluck, David, DO	Feconda, Fury, PharmD	Orr, Lavdena, MD	Smith, Kirby, MD
Caton, Kirt, MD	Himmelstein, Bruce, MD	Peters, Eric, PharmD	Weart, Wayne, PharmD
Cooper, Don, MD	Hockmuth, Robert, MD	Peterson, Andrew, PharmD	Whitfield, Rani, MD
Davis, Tracey, PharmD	Kryger, Emily, PharmD	Petkash, David, MD	Wise, Rodney, MD

Excused Voting Members

Beam, Donald, MD	Higgins, Lily, MD	Muller, Betty, MD
Brinley, Floyd (John), MD	Michael, Kendra, MD	

Invited Guests Present

Baird, Bethany, CPhT	Hunter, Mandy, PharmD	Seitz, Ally, PharmD
Broussard, Rachel	Kassim, Toks, PharmD	Smith, Bryan, MD
Carreras, Linda	Megargell, Lauren, PharmD	Stadler, Luke
Cheely, George, MD	Meny, Christopher, PharmD	Thomas, Mali, CPhT
Clement, Kathleen	Ng, Tammy, CPhT	Vodoor, Calla, PharmD
Colvin, Mike, PharmD	Oaster, Patty	Weiss, Erich, PharmD
Dick, Natalie, CPhT	O'Meara, Brian	Wiseman, Arlene, PharmD

Issue	Discussion	Conclusion/Results	Action/ Person Responsible
1. Call to Order	The meeting was called to order at 6:02 PM EST Welcomed all external and internal participants.	Informational Only	Bruce Himelstein
2. Conflict of Interest Disclosure	No conflicts announced	Informational Only	Sheena Cherian
3. BCC Positive Change		Informational Only	Chris Meny
4. Review and approval of May P&T minutes		Informational Only Motion: Rani Whitfield Second: Robert Hockmuth	Sheena Cherian
5. Old Business			
Amyotrophic Lateral Sclerosis (ALS) agents	<p align="center">PerformRx makes the following recommendation:</p> <p>█ █ █</p> <p>█ █ █</p> <p>█ █ █</p>	<p align="center">Committee approved as recommended</p> <p>Motion: David Batluck Second: Donald Cooper</p>	PerformRx will update the criteria and formulary/PDL with any changes

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>		
Rituximab	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Donald Cooper</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

[Redacted]

[Redacted]






[Redacted]

KF/AHC/ [Redacted]

- Include diagnosis specific criteria for approval of Dermatomyositis and Polymyositis

[Redacted]

Notes: This was retired for BCC because of PA-0019.

			
<p>SMN2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy (SMA)</p>	<p>PerformRx makes the following recommendation:</p> 	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Donald Cooper</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

[REDACTED]

[REDACTED]

[REDACTED]



[REDACTED]

[REDACTED]

KF/AHC/ [REDACTED]

- Exclude concomitant use with Evrysdi and Spinraza since they have a similar mechanism and there is no data on using both agents together.
- Remove the age restriction on Evrysdi as it is now approved for use in infants from birth

[REDACTED]

			
<p>Continuous Glucose Monitors with PA Criteria</p>	<p>PerformRx makes the following recommendation:</p> 	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Eric Peters</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

- Remove the prior authorization requirement on FreeStyle Libre 14 Day and FreeStyle Libre 2, and add a step therapy requirement through insulin.
- Add FreeStyle Libre 3 Sensor to Tier 3 of the formulary with a step therapy requirement through insulin and a quantity limit of 2 sensors per 28 days
- Remove the prior authorization requirement on Dexcom G6, and add a step therapy requirement through insulin
- Approve the updated Continuous Glucose Monitors prior authorization criteria with the following changes
 - Add new FreeStyle Libre 3 to the drug list as a preferred CGM option
 - Add Dexcom G6 as a preferred CGM option
 - Remove prescriber restrictions
 - Streamline criteria to allow use of a preferred CGM when the member is on insulin
 - Allow continuation of therapy for a non-preferred CGM product

[REDACTED]

	<p>KF/AHC/ [REDACTED]</p> <ul style="list-style-type: none">• Make no changes to the medications in this class <p>[REDACTED]</p> <p>[REDACTED]</p>		
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

B. Single Products:		:	
Pyrukynd with PA Criteria	<p style="text-align: center;">PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>KF/AHC/ [REDACTED]</p> <ul style="list-style-type: none">• Add Pyrukynd (mitapivat) to Tier 4 with a prior authorization requirement• Approve the Pyruvate Kinase Activators prior authorization criteria <p>[REDACTED]</p> <p>[REDACTED]</p>	<p style="text-align: center;">Committee approved as recommended</p> <p>Motion: Robert Hockmuth Second: Donald Cooper</p>	<p style="text-align: center;">PerformRx will update the criteria and formulary/PDL with any changes</p>

<p>Carvykti with PA Criteria</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Robert Hockmuth Second: Donald Cooper</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<ul style="list-style-type: none"> • Add Carvykti (ciltacabtagene autoleucel) to tier 4 of the formulary with a prior authorization requirement. • Approve the updated B-Cell Maturation Antigen (BCMA) Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy prior authorization criteria with the following changes: <ul style="list-style-type: none"> • Include Carvykti in the criteria • Ensure members have not previously received therapy with a BCMA CAR-T Therapy <div data-bbox="485 621 1163 1117" style="background-color: black; width: 100%; height: 100%;"></div>		
Vvoice with PA Criteria	<p style="text-align: center;">PerformRx makes the following recommendation:</p> <div data-bbox="485 1339 585 1386" style="background-color: black; width: 100%; height: 100%;"></div>	<p style="text-align: center;">Committee approved as recommended</p> <p>Motion: Robert Hockmuth Second: Donald Cooper</p>	<p style="text-align: center;">PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>KF/AHC/ [REDACTED]</p> <ul style="list-style-type: none"> • Add Camzyos (mavacamten) to the supplemental formulary (T3) with prior authorization • Approve the newly developed Camzyos prior authorization criteria <p>[REDACTED]</p> <p>[REDACTED]</p>		
<p>8. New Products</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Wayne Weart Second: Andrew Peterson</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

[REDACTED]

[REDACTED]

[REDACTED]

**Add to Specialty Tier with a PA requirement for
and KF/AHC/**

- Amvuttra
- Ztalmy

**Add to the Specialty Tier with drug specific PA
requirement for KF/AHC/**

- Bortezomib
- Pluvicto
- Radicava ORS

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Remain non-formulary for KF/AHC/ [REDACTED]

- Quiviq

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

**Remain non-formulary/non-preferred for
KF/AHC/ [REDACTED]**

- Tyvaso DPI

**Remain non-formulary/non-preferred for
KF/AHC/ [REDACTED]**

- Alymsys

**Remain non-formulary/non-preferred for
KF/AHC/ [REDACTED]**

- Epsolay
- Posimir
- Priorix
- ProvayBlue
- Ticovac
- Verkazia

	<ul style="list-style-type: none"> • XCelliStem <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>		
9. Prior Authorization Criteria Review			
A. Prior Authorization Criteria Annual Review			
Acthar H.P. (corticotropin)	<p style="text-align: center;">PerformRx makes the following recommendation:</p> <p>[REDACTED]</p>	<p style="text-align: center;">Committee approved as recommended</p> <p>Motion: David Batluck Second: Donald Cooper</p>	<p style="text-align: center;">PerformRx will update the criteria and formulary/PDL with any changes</p>

[Redacted]

[Redacted]

KF/AHC/ [Redacted]

- Update title to reflect generic name
- Include the recently reintroduced Corticotrophin as a preferred agent over Acthar as a cost effective alternative treatment option
- Require a trial and failure of Corticotrophin prior Acthar for all indications with the exception of infantile spasms as Corticotrophin does not share this indication

[Redacted]

	<p>[REDACTED]</p>		
<p>Anti-Amyloid Monoclonal Antibodies [Aduhelm]</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Donald Cooper</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

[Redacted]

[Redacted]

KF/AHC/

- Require members requesting an anti-amyloid mAb approved by the FDA based on the efficacy of a surrogate endpoint to be enrolled in a clinical trial conducted under an investigational new drug application to align with recent CMS national coverage determination

[Redacted]

	<p>[REDACTED]</p>		
<p>Anti-FGF23 Monoclonal Antibodies</p>	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: David Batluck Second: Donald Cooper</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>KF/AHC/ [REDACTED]</p> <ul style="list-style-type: none">• Approve the Anti-FGF23 Monoclonal Antibodies prior authorization criteria with no clinical changes <p>[REDACTED]</p>		
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

	<p>█</p> <p>█</p> <p>█</p> <p>█</p> <p>█</p> <p>█</p>		
--	---	--	--

Complement Inhibitors	<p>PerformRx makes the following recommendation:</p> <p>█</p> <p>█</p> <p>█</p> <p>█</p> <p>█</p> <p>█</p>	<p>Committee approved as recommended</p> <p>Motion: Lavdena Orr Second: Wayne Weart</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>
-----------------------	---	--	--

KF/AHC/ [REDACTED]

- Remove all additional authorization criteria with the exception of the requirement of a diagnosis of diabetes and use multiple daily insulin injections
- Add Omnipod 5 to the formulary as a preferred diabetic supply on plan specific appropriate tier with a prior authorization requirement

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>		
--	---	--	--

Specialty Drugs

PerformRx makes the following recommendation:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Committee approved as recommended

Motion: Bruce Himelstein
Second: Kirt Caton

PerformRx will update the criteria and formulary/PDL with any changes

	<p>[REDACTED]</p> <p>KF/AHC/ [REDACTED]</p> <ul style="list-style-type: none">• Require a trial with all available biosimilars <p>[REDACTED]</p>		
Verquvo	<p>PerformRx makes the following recommendation:</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>Committee approved as recommended</p> <p>Motion: Bruce Himmelstein Second: Kirt Caton</p>	<p>PerformRx will update the criteria and formulary/PDL with any changes</p>

Synagis

PerformRx makes the following recommendation:

[Redacted]

[Redacted]

[Redacted]

Committee approved as recommended

Motion: Bruce Himmelstein
Second: Kirt Caton

PerformRx will update the criteria and formulary/PDL with any changes

[REDACTED]






[REDACTED]

[REDACTED]

KF/AHC/ [REDACTED]

- Reduce number of authorized doses during an RSV season back down to 5 as only 5 doses are recommended during a season. Note that the 2021 spring/summer season was considered a separate RSV season from the 2021-2022 winter RSV season.

[REDACTED]



			
Brineura	<p>PerformRx makes the following recommendation:</p> 	<p>Committee approved as recommended</p> <p>Motion: Donald Cooper Second: Robert Hockmuth</p>	<p>No Changes</p>

	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>KF/AHC/ [REDACTED]</p> <ul style="list-style-type: none">• Approve the Brineura prior authorization criteria for with no clinical changes <p>[REDACTED]</p>		
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

	<p>I [REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>KF/AHC/ [REDACTED]</p> <ul style="list-style-type: none">• Approve the Mucopolysaccharidosis II (Hunter Syndrome) Agents with no changes <p>[REDACTED]</p>	<p>Second: Robert Hockmuth</p>	
<p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

Vimizim	PerformRx makes the following recommendation:	Committee approved as recommended	No Changes
	<p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>[REDACTED]</p> <p>KF/AHC [REDACTED]</p> <ul style="list-style-type: none"> • Approve the Vimizim prior authorization criteria with no changes <p>[REDACTED]</p>	<p>Motion: Donald Cooper Second: Robert Hockmuth :</p> <p>[REDACTED]</p>	<p>[REDACTED]</p>

C. New Prior Authorization Criteria			
Vuity	<p align="center">PerformRx makes the following recommendation:</p> <p>█ █</p> <p>█ █</p> <p>KF/AHC/█</p> <ul style="list-style-type: none"> • Approve the newly developed Vuity prior authorization criteria <p>█ █</p>	<p align="center">Committee approved as recommended</p> <p>Motion: Lavenda Orr Second: Chris Meny</p>	<p align="center">PerformRx will update the criteria and formulary/PDL with any changes</p>
█ █			
█ █	<p>█</p> <p>█ █</p> <p>█ █</p>	<p>█ █</p> <p>█ █</p>	<p>█ █</p>

	 		
11. Recalls	<p align="center">4/14/2022 – 7/7/2022</p> <p>There were no Class 1 or 2 recalls impacting all lots for medications listed within FDB or Medispan</p>	Informational	PerformRx
Adjourn	The meeting adjourned at 7:39	N/A	Bruce Himmelstein
	The next meeting October 24th, 2022		



Bruce Himmelstein, MD MBA
VP, Utilization Management Physician

November 9, 2022
Date